Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals appoints Dr. Matt Cohen to its board of directors

Neutral Impact 2 of 5 leadership Written later

Arrowhead Pharmaceuticals appointed Dr. Matt Cohen as a director effective June 12, 2026, as disclosed in a June 16, 2026 Form 8-K. Dr. Cohen previously spent about two decades in healthcare investing and portfolio management, most recently as Managing Director at Vida Ventures, and his board seat adds a director with healthcare investment experience.

Key points

  • Board appointment effective June 12, 2026
  • Dr. Cohen is Managing Director at Vida Ventures and previously served at JP Morgan Asset Management from 2005
  • Sign-on grant of restricted stock units valued at $887,000, scheduled to vest over three years
  • Dr. Cohen will receive standard non-employee director compensation and enter the Company's standard indemnity agreement

The filing

CompanyArrowhead Pharmaceuticals (ARWR)
Form8-K, current report
Filed with the SECJun 16, 2026, 4:02 PM ET
Accession number0000879407-26-000050

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.